NCT04829604 2026-03-09ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Ambrx, Inc.Phase 2 Active not recruiting72 enrolled
NCT05426486 2024-10-30A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsShengjing HospitalPhase 2/3 Active not recruiting136 enrolled